This article was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Ther Innov Regul Sci. 2019 Jan 7:2168479018811889 under a Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by…
Historic drug sales data can help with market sizing. By examining sales trends over time you can gauge the attractiveness of the market entry. For patented drugs examining sales trends…
The post How to Use Drug Sales Data to Refine Your Channel Strate…
In evaluating generic entry opportunities many factors must be considered. DrugPatentWatch has comprehensive resources to aid in evaluating patent and regulatory constraints, and those are described in further detail in…
The post How to Use Drug Price …
How to Use Drug Price Data for Generic Entry Pricing Read Post »
The generic pharmaceutical industry exists at the intersection of business, science, law, and government regulation. To be perform well in any of these disparate areas requires deep specialization (e.g. a…
The post The Generic Challenge appeared first …
This article was originally published by Philippe Lahorte in World Patent Information Volume 54, Supplement, September 2018, Pages S18-S22 Under a Creative Commons license. Abstract This article provides an insight…
The post Inside the mind of an EPO e…
We thought you might be interested in some of the great reviews we’re getting over at software review site G2Crowd. Take a look at a few of the reviews below:…
The post See What Others are Saying About DrugPatentWatch appeared first on DrugPatentWatch …
See What Others are Saying About DrugPatentWatch Read Post »
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’ market-leading platform, bringing together the most relevant information to support…
The post DrugPa…
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
The post Branded Generics: What They Are and Why They’re Profitable appeared first on DrugPatent…
Branded Generics: What They Are and Why They’re Profitable Read Post »
Kenneth L. Dorsney, Editor-in-Chief 1,035 pages Buy from Amazon Pre-ANDA litigation is the companion to ANDA Litigation, which I recommend for its guidance on all matters occuring after a drug…
The post Pre-ANDA Litigation: Strategies and Tactics for D…
Brex is the first corporate credit card specifically for biotech and pharma startups. They provide corporate cards with no founder liability, a best in class rewards program, 10-20x higher spending limits…
The post Brex: The first corporate credit card…
Brex: The first corporate credit card specifically for biotech and pharma startups Read Post »
Get new actionable insights and updates from BiotechBlog
